1. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Issue 10273 (6th February 2021) Authors: Reich, Kristian; Papp, Kim A; Blauvelt, Andrew; Langley, Richard G; Armstrong, April; Warren, Richard B; Gordon, Kenneth B; Merola, Joseph F; Okubo, Yukari; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Vanvoorden, Veerle; Lebwohl, Mark Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Issue 10201 (7th September 2019) Authors: Reich, Kristian; Armstrong, April W; Langley, Richard G; Flavin, Susan; Randazzo, Bruce; Li, Shu; Hsu, Ming-Chun; Branigan, Patrick; Blauvelt, Andrew Journal: Lancet Issue: Volume 394:Issue 10201(2019) Page Start: 831 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗